Science Corp's $230M Bet: Why Vision, Not Thought Control, Will Win BCI

Science Corp just closed a $230 million Series C at a $1.5 billion valuation, and the most important detail is not the dollar figure. It is that Max Hodak, who cofounded Neuralink alongside Elon Musk, has built a company that could beat his former venture to commercial market by taking a path almost nobody in Silicon Valley would have chosen: fixing eyes instead of reading minds.

The round, led by Lightspeed Venture Partners with participation from Khosla Ventures, Y Combinator, Quiet Capital, and IQT (the CIA's venture arm, a detail worth lingering on), brings Science Corp's total funding to $490 million. But the strategy underneath is what separates this company from the BCI herd. While Neuralink chases the technically dazzling goal of direct cortical interfaces, and Synchron threads stent-like electrodes through blood vessels, Science Corp has placed its primary commercial bet on a grain-of-rice-sized chip that sits in the eye. That chip, called PRIMA, is now in CE mark review with European regulators and could be approved by mid-2026. If that timeline holds, Science Corp becomes the first brain-computer interface company in history with a product you can actually buy.

The Pixium Vision Acquisition: Picking Up What France Dropped

The PRIMA implant did not originate at Science Corp. It was developed by Pixium Vision, a French medtech company that had been working on subretinal prosthetics for over a decade, building on foundational research by Stanford professor Daniel Palanker. The technology is elegant in its simplicity: a wireless, subretinal chip composed of hundreds of photovoltaic pixels, paired with camera-equipped glasses that project infrared light onto the implant. Each pixel generates a small electric field when hit by infrared, stimulating the remaining bipolar cells in the retina. No battery. No wires threading into the brain. Just a tiny solar panel doing what damaged photoreceptors no longer can.

Pixium had run clinical trials across Europe and the U.S. spanning 47 patients with advanced dry age-related macular degeneration. The results were remarkable: 80% of patients showed meaningful improvement in visual acuity, with many able to read letters, numbers, and words. This was not vague "light perception" improvement. Researchers called it "form vision," the ability to recognize visual elements as parts of a larger object. It was the first definitive demonstration of form vision restoration in humans.

Then Pixium ran out of money. The company was placed into liquidation by a French commercial court in early 2024, and Science Corp swooped in to acquire its assets. The Paris Commercial Court approved the deal in April 2024, and Science Corp inherited not just the technology but 38 patients enrolled in an ongoing pivotal study. Hodak's public framing was humanitarian: these patients could not be left hanging. The strategic reality was that Science Corp acquired a decade of clinical data, regulatory groundwork, and a technology that had already proven it worked in human eyes, likely for a fraction of what it cost to develop.

This is the kind of move that defines category winners. Pixium's failure was not a technology failure. It was a capital markets failure in European medtech. Science Corp turned a French startup's financial collapse into an express lane to regulatory approval.

The Contrarian Playbook: Why Eyes Beat Brains

The BCI industry has a narrative problem. Thanks largely to Neuralink's extraordinary media presence, brain-computer interfaces are synonymous in the public imagination with electrode arrays penetrating cortical tissue to decode thoughts. This framing makes for spectacular demos and fervent Reddit threads. It also describes a regulatory and technical nightmare that is years from commercial reality.

Cortical implants face a cascade of challenges that retinal implants largely sidestep. Penetrating brain tissue triggers immune responses that degrade signal quality over time. The surgical procedure is invasive neurosurgery requiring craniotomy. The FDA pathway for a device that sits inside the brain is, by design, grueling. Neuralink has implanted 12 people as of late 2025, and while results have been impressive for those patients, the company is still firmly in the clinical trial phase with over 10,000 people on its waiting list.

PRIMA, by contrast, targets the eye, an organ that is far more accessible surgically, far better understood immunologically, and governed by a regulatory framework that has decades of precedent from intraocular lenses and retinal prosthetics. The subretinal space is a relatively immunoprivileged environment. The surgery is performed by vitreoretinal surgeons, a large and well-trained specialty, not neurosurgeons operating with robotic assistance. And the target condition, advanced dry macular degeneration, affects roughly 200 million people globally. There is no approved treatment.

This is the insight that Hodak's experience at Neuralink crystallized: the fastest path to commercial BCI is not the most technically ambitious one. It is the one that navigates regulatory, surgical, and reimbursement infrastructure that already exists. Germany, Science Corp's likely first market, has established pathways for granting early access to new medical technologies. The CE mark process, while rigorous, moves faster than FDA approval for novel neural devices. By choosing eyes over brains and Europe over America, Science Corp is running a regulatory arbitrage that could give it years of head start.

The Real Competitive Map: Five Companies, Five Bets

The BCI landscape in 2026 looks nothing like it did even two years ago. Five companies are making credible runs at commercial implantable neural interfaces, each with a fundamentally different thesis about how to wire silicon to biology.

Neuralink remains the most visible player, with plans to begin high-volume production of its Link implant in 2026 using an almost fully automated surgical robot. Its approach, threading 1,024 ultra-thin electrodes into the motor cortex, delivers the highest channel count of any implant but requires the most invasive procedure. Neuralink's target conditions are severe paralysis and eventually ALS, a devastating but relatively small patient population.

Synchron has taken the vascular route, threading a stent-like device called Stentrode through blood vessels to reach the brain's surface without open surgery. The company has FDA approval for trials and has formed partnerships with Apple and NVIDIA, positioning itself at the intersection of BCI and consumer tech. Its foundation model, Chiral, trained on human neural activity data, hints at ambitions well beyond medical devices.

Paradromics received FDA breakthrough device designation and clearance to begin brain implant trials in early 2026, targeting motor and speech recovery with high-bandwidth cortical arrays. Its approach uses thousands of microwires bonded to a CMOS chip, aiming for the data throughput of Neuralink with what it claims is a more manufacturable design.

Precision Neuroscience, founded by a Neuralink cofounder (a pattern worth noting), uses thin-film electrode arrays placed on the brain's surface rather than penetrating it. This epidural approach trades some signal resolution for dramatically reduced surgical risk and reversibility.

Science Corp stands apart because it is the only company whose lead product does not touch the brain at all. While its longer-term biohybrid program, which grows engineered neurons from stem cells onto a cortical surface device, is genuinely cutting-edge neuroscience, the commercial spearhead is a retinal implant. This is not a compromise. It is a strategy.

The competitive dynamics here are not winner-take-all. These companies are targeting different organs, different conditions, and different regulatory pathways. But Science Corp's strategy creates a specific advantage: revenue. A company that reaches market in 2026 or 2027 generates cash flow, clinical data at scale, and manufacturing experience while its competitors are still enrolling trial participants.

Second-Order Effects: What Happens After the First Sale

If Science Corp achieves CE mark approval and begins commercial sales in Germany by late 2026, the ripple effects across the BCI industry will be significant.

Reimbursement precedent. The moment a national health system agrees to pay for a brain-computer interface device, however broadly you define the category, it establishes a template. Pricing negotiations, health technology assessments, outcome metrics: all of this gets codified for the first time. Every subsequent BCI company benefits from this groundwork, but Science Corp gets to shape how it is structured.

Investor confidence shift. BCI has been a "deep tech" category where venture capital has historically required a high tolerance for regulatory risk and long timelines. A commercial product changes the conversation from "will this ever work?" to "how big is the market?" Expect fundraising across the entire sector to accelerate, with later-stage and crossover investors entering a space previously dominated by early-stage risk capital. The $3.2 billion BCI market projected for 2025 is forecast to reach $12.9 billion by 2034 at a 16.7% CAGR, but a commercial product could compress that timeline.

The IQT investment matters more than it looks. IQT, In-Q-Tel, is the strategic investment arm of the U.S. intelligence community. Its participation in Science Corp's round signals that government and defense agencies see brain-computer interfaces as a strategic technology, not merely a medical one. Science Corp's biohybrid cortical program, which involves growing engineered neurons that form biological connections with existing neural circuits, is exactly the kind of dual-use technology that attracts defense interest. The retinal implant gets the company to market. The biohybrid program is the long game.

Talent and acquisition dynamics. Science Corp was built, in part, from the wreckage of other companies. Hodak left Neuralink. PRIMA was rescued from Pixium's liquidation. This pattern of experienced founders leaving well-funded competitors to start more strategically focused ventures is not unique to BCI, but the concentration of it is striking. Three of the five leading BCI companies were founded by people who left Neuralink. The diaspora is becoming the industry.

The Biohybrid Wildcard

Science Corp's PRIMA implant is the near-term commercial story, but its biohybrid brain-computer interface program is the one that could redefine the entire field. The concept is radical: instead of relying solely on electrodes to read electrical signals from neurons, Science Corp is growing engineered neurons from stem cells onto a waffle-like substrate that sits on the brain's surface. These lab-grown neurons then form biological synaptic connections with the patient's own neural circuits.

If this works at scale, it solves the fundamental problem that plagues every electrode-based BCI: signal degradation. When you push metal or silicon into brain tissue, the body's immune response gradually encapsulates the foreign material in scar tissue, degrading the signal over months and years. Biological neurons that integrate with native tissue would not trigger this response. They would become part of the brain.

The technical challenges are immense. Controlling the differentiation and connectivity of engineered neurons in vivo, ensuring they form useful connections rather than random ones, preventing tumor formation from stem cell derivatives, and scaling manufacturing of living biological devices all remain open problems. But the approach represents a genuine paradigm shift from the electrode-based architectures that every other BCI company is iterating on. It is the difference between building a better microphone to listen to the brain and growing a new ear that the brain talks to natively.

This dual-track strategy, a near-term retinal implant that generates revenue and regulatory experience paired with a long-term biohybrid program that could leapfrog the entire electrode paradigm, is what makes the $1.5 billion valuation look less like hype and more like a bet on optionality.

What Comes Next

Three predictions for the BCI industry over the next 18 months.

First, Science Corp will receive CE mark approval for PRIMA in Europe before any cortical BCI reaches commercial market anywhere. The regulatory pathway is clearer, the clinical data is stronger, and the surgical risk profile is lower. Germany will be the launch market, and France will follow quickly, partly as a matter of national pride given PRIMA's origins at Pixium Vision.

Second, Neuralink will respond by accelerating its own regulatory strategy outside the United States. Musk has already indicated interest in markets with faster approval pathways. The competitive pressure of a former cofounder beating Neuralink to market will be a powerful motivator, and Neuralink's robotic surgery platform gives it a deployment advantage in markets without large neurosurgery workforces.

Third, at least two major medical device companies, likely Medtronic and Abbott, will make acquisitions or significant strategic investments in BCI startups by the end of 2027. The combination of proven clinical results, approaching commercial milestones, and a market projected to grow at nearly 17% annually makes this sector too strategic for incumbents to ignore. Science Corp's acquisition of Pixium was a preview of this consolidation wave, but the next round will involve acquirers with global distribution networks and reimbursement relationships that no startup can replicate.

Max Hodak left Neuralink in 2021 and built a company that could reach patients before his former venture reaches production. He did it not by out-engineering Musk's team, but by choosing a different organ, a different continent, and a different definition of what "brain-computer interface" means. In a field obsessed with the technical frontier, the first commercial winner may be the company that aimed for the achievable instead of the extraordinary.